Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis

摘要: The coverage of prevention and treatment strategies for ischemic heart disease stroke is very low in Ethiopia. In view Ethiopia’s meager healthcare budget, it important to identify the most cost-effective interventions further scale-up. This paper’s objective assess cost-effectiveness (IHD) an Ethiopian setting. Fifteen single sixteen intervention packages were assessed from a provider perspective. World Health Organization’s Choosing Interventions that are Cost-Effective model cardiovascular was updated with available country-specific inputs, including demography, mortality price traded non-traded goods. Costs health benefits discounted at 3 % per year. Incremental ratios reported US$ disability adjusted life year (DALY) averted. Sensitivity analysis undertaken robustness our results. Combination drug individuals having >35 % absolute risk CVD event next 10 years intervention. costs US$67 DALY averted about US$7 million annually. Treatment acute myocardial infarction (AMI) (costing US$1000–US$7530 averted) secondary IHD US$1060–US$10,340 become more efficient when delivered integrated packages. At annual willingness-to-pay (WTP) level US$3 million, package consisting aspirin, streptokinase, ACE-inhibitor beta-blocker AMI has highest probability being cost-effective, whereas as WTP increases to > US$7 combination stands out strategy. Cost-effectiveness relatively sensitive halving effectiveness estimates compared doubling drugs laboratory tests. Ethiopia, escalating burden its factors warrants timely action. We have demonstrated selected could be scaled up modest budget increase. implications interventions’ cost-effective. study provides valuable evidence setting priorities essential